Piperacllin Versus Placebo in Patients Undergoing Surgery for Acute Cholecystitis
Status:
Completed
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
The benefit from antibiotic prophylaxis in patients undergoing laparoscopic cholecystectomy
for acute cholecystitis is insufficiently known. The aim of the present double-blind
randomized controlled is to compare piperacilin with placebo in patients undergoing
cholecystectomy for acute cholecystitis with anamnesis not exceeding 5 days. Altogether 100
patients are intended to be included. Primary endpoint is biliary contamination. Secondary
endpoints are postoperative hospital stay, health-related quality of life, pain perception,
postoperative markers of inflammatory response, surgical site infections, infectious
complications other than surgical site infections, health economy and relationship between
symptom anamnesis and bile contamination.
Phase:
Phase 3
Details
Lead Sponsor:
Karolinska Institutet
Treatments:
Penicillanic Acid Piperacillin Piperacillin, Tazobactam Drug Combination Tazobactam